放射性リガンド療法のグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Radioligand Therapy Market Insights, Forecast to 2028

• レポートコード：QY2207E10044 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療機器

• 販売価格（消費税別）

Single User	￥725,200 (USD4,900)	▷ お問い合わせ
Multi User	￥1,087,800 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,450,400 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界の放射性リガンド療法の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に放射性リガンド療法の世界市場のxxx％を占める「アクチニウム225（Ac-225）」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「神経内分泌腫瘍」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の放射性リガンド療法の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの放射性リガンド療法市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの放射性リガンド療法市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 放射性リガンド療法のグローバル主要メーカーには、Novartis、Advanced Accelerator Applications、Mercy Radiology、POINT Biopharma Global Inc、Fusion Pharma、Telix Pharmaceuticals Ltd、Lantheus Holdings, Inc、Bayer AG、Curium Pharma、Precirixなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 放射性リガンド療法市場は、種類と用途によって区分されます。世界の放射性リガンド療法市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 アクチニウム225（Ac-225）、ルテチウム177（Lu-177）、ガリウム68（Ga-68）、フッ素18（F-18）、その他放射性核種 【用途別セグメント】 神経内分泌腫瘍、前立腺がん 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 放射性リガンド療法製品概要 - 種類別市場（アクチニウム225（Ac-225）、ルテチウム177（Lu-177）、ガリウム68（Ga-68）、フッ素18（F-18）、その他放射性核種） - 用途別市場（神経内分泌腫瘍、前立腺がん） - 調査の目的 ・エグゼクティブサマリー - 世界の放射性リガンド療法販売量予測2017-2028 - 世界の放射性リガンド療法売上予測2017-2028 - 放射性リガンド療法の地域別販売量 - 放射性リガンド療法の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別放射性リガンド療法販売量 - 主要メーカー別放射性リガンド療法売上 - 主要メーカー別放射性リガンド療法価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（アクチニウム225（Ac-225）、ルテチウム177（Lu-177）、ガリウム68（Ga-68）、フッ素18（F-18）、その他放射性核種） - 放射性リガンド療法の種類別販売量 - 放射性リガンド療法の種類別売上 - 放射性リガンド療法の種類別価格 ・用途別市場規模（神経内分泌腫瘍、前立腺がん） - 放射性リガンド療法の用途別販売量 - 放射性リガンド療法の用途別売上 - 放射性リガンド療法の用途別価格 ・北米市場 - 北米の放射性リガンド療法市場規模（種類別、用途別） - 主要国別の放射性リガンド療法市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの放射性リガンド療法市場規模（種類別、用途別） - 主要国別の放射性リガンド療法市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の放射性リガンド療法市場規模（種類別、用途別） - 主要国別の放射性リガンド療法市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の放射性リガンド療法市場規模（種類別、用途別） - 主要国別の放射性リガンド療法市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの放射性リガンド療法市場規模（種類別、用途別） - 主要国別の放射性リガンド療法市場規模（トルコ、サウジアラビア） ・企業情報 Novartis、Advanced Accelerator Applications、Mercy Radiology、POINT Biopharma Global Inc、Fusion Pharma、Telix Pharmaceuticals Ltd、Lantheus Holdings, Inc、Bayer AG、Curium Pharma、Precirix ・産業チェーン及び販売チャネル分析 - 放射性リガンド療法の産業チェーン分析 - 放射性リガンド療法の原材料 - 放射性リガンド療法の生産プロセス - 放射性リガンド療法の販売及びマーケティング - 放射性リガンド療法の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 放射性リガンド療法の産業動向 - 放射性リガンド療法のマーケットドライバー - 放射性リガンド療法の課題 - 放射性リガンド療法の阻害要因 ・主な調査結果

Market Analysis and Insights: Global Radioligand Therapy Market
The global Radioligand Therapy market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Actinium 225 (Ac-225) accounting for % of the Radioligand Therapy global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Neuroendocrine Neoplasms segment is altered to an % CAGR throughout this forecast period.
China Radioligand Therapy market size is valued at US$ million in 2021, while the North America and Europe Radioligand Therapy are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Radioligand Therapy landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Radioligand Therapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Radioligand Therapy market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Radioligand Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Radioligand Therapy market.
Global Radioligand Therapy Scope and Market Size
Radioligand Therapy market is segmented by players, region (country), by Used Radionuclides and by Application. Players, stakeholders, and other participants in the global Radioligand Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Used Radionuclides and by Application for the period 2017-2028.
Segment by Used Radionuclides
Actinium 225 (Ac-225)
Lutetium 177 (Lu-177)
Gallium 68 (Ga-68)
Fluorine 18 (F-18)
Other Radionuclides
Segment by Application
Neuroendocrine Neoplasms
Prostate Cancer
By Company
Novartis
Advanced Accelerator Applications
Mercy Radiology
POINT Biopharma Global Inc
Fusion Pharma
Telix Pharmaceuticals Ltd
Lantheus Holdings, Inc
Bayer AG
Curium Pharma
Precirix
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

---

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Used Radionuclides
1.2.1 Global Radioligand Therapy Market Size Growth Rate by Used Radionuclides, 2017 VS 2021 VS 2028
1.2.2 Actinium 225 (Ac-225)
1.2.3 Lutetium 177 (Lu-177)
1.2.4 Gallium 68 (Ga-68)
1.2.5 Fluorine 18 (F-18)
1.2.6 Other Radionuclides
1.3 Market by Application
1.3.1 Global Radioligand Therapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Neuroendocrine Neoplasms
1.3.3 Prostate Cancer
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Radioligand Therapy Market Perspective (2017-2028)
2.2 Radioligand Therapy Growth Trends by Region
2.2.1 Radioligand Therapy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Radioligand Therapy Historic Market Size by Region (2017-2022)
2.2.3 Radioligand Therapy Forecasted Market Size by Region (2023-2028)
2.3 Radioligand Therapy Market Dynamics
2.3.1 Radioligand Therapy Industry Trends
2.3.2 Radioligand Therapy Market Drivers
2.3.3 Radioligand Therapy Market Challenges
2.3.4 Radioligand Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Radioligand Therapy Players by Revenue
3.1.1 Global Top Radioligand Therapy Players by Revenue (2017-2022)
3.1.2 Global Radioligand Therapy Revenue Market Share by Players (2017-2022)
3.2 Global Radioligand Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Radioligand Therapy Revenue
3.4 Global Radioligand Therapy Market Concentration Ratio
3.4.1 Global Radioligand Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radioligand Therapy Revenue in 2021
3.5 Radioligand Therapy Key Players Head office and Area Served
3.6 Key Players Radioligand Therapy Product Solution and Service
3.7 Date of Enter into Radioligand Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Radioligand Therapy Breakdown Data by Used Radionuclides
4.1 Global Radioligand Therapy Historic Market Size by Used Radionuclides (2017-2022)
4.2 Global Radioligand Therapy Forecasted Market Size by Used Radionuclides (2023-2028)
5 Radioligand Therapy Breakdown Data by Application
5.1 Global Radioligand Therapy Historic Market Size by Application (2017-2022)
5.2 Global Radioligand Therapy Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Radioligand Therapy Market Size (2017-2028)
6.2 North America Radioligand Therapy Market Size by Used Radionuclides
6.2.1 North America Radioligand Therapy Market Size by Used Radionuclides (2017-2022)
6.2.2 North America Radioligand Therapy Market Size by Used Radionuclides (2023-2028)
6.2.3 North America Radioligand Therapy Market Share by Used Radionuclides (2017-2028)
6.3 North America Radioligand Therapy Market Size by Application
6.3.1 North America Radioligand Therapy Market Size by Application (2017-2022)
6.3.2 North America Radioligand Therapy Market Size by Application (2023-2028)
6.3.3 North America Radioligand Therapy Market Share by Application (2017-2028)
6.4 North America Radioligand Therapy Market Size by Country
6.4.1 North America Radioligand Therapy Market Size by Country (2017-2022)
6.4.2 North America Radioligand Therapy Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Radioligand Therapy Market Size (2017-2028)
7.2 Europe Radioligand Therapy Market Size by Used Radionuclides
7.2.1 Europe Radioligand Therapy Market Size by Used Radionuclides (2017-2022)
7.2.2 Europe Radioligand Therapy Market Size by Used Radionuclides (2023-2028)
7.2.3 Europe Radioligand Therapy Market Share by Used Radionuclides (2017-2028)
7.3 Europe Radioligand Therapy Market Size by Application
7.3.1 Europe Radioligand Therapy Market Size by Application (2017-2022)
7.3.2 Europe Radioligand Therapy Market Size by Application (2023-2028)
7.3.3 Europe Radioligand Therapy Market Share by Application (2017-2028)
7.4 Europe Radioligand Therapy Market Size by Country
7.4.1 Europe Radioligand Therapy Market Size by Country (2017-2022)
7.4.2 Europe Radioligand Therapy Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Radioligand Therapy Market Size (2017-2028)
8.2 Asia-Pacific Radioligand Therapy Market Size by Used Radionuclides
8.2.1 Asia-Pacific Radioligand Therapy Market Size by Used Radionuclides (2017-2022)
8.2.2 Asia-Pacific Radioligand Therapy Market Size by Used Radionuclides (2023-2028)
8.2.3 Asia-Pacific Radioligand Therapy Market Share by Used Radionuclides (2017-2028)
8.3 Asia-Pacific Radioligand Therapy Market Size by Application
8.3.1 Asia-Pacific Radioligand Therapy Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Radioligand Therapy Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Radioligand Therapy Market Share by Application (2017-2028)
8.4 Asia-Pacific Radioligand Therapy Market Size by Region
8.4.1 Asia-Pacific Radioligand Therapy Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Radioligand Therapy Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Radioligand Therapy Market Size (2017-2028)
9.2 Latin America Radioligand Therapy Market Size by Used Radionuclides
9.2.1 Latin America Radioligand Therapy Market Size by Used Radionuclides (2017-2022)
9.2.2 Latin America Radioligand Therapy Market Size by Used Radionuclides (2023-2028)
9.2.3 Latin America Radioligand Therapy Market Share by Used Radionuclides (2017-2028)
9.3 Latin America Radioligand Therapy Market Size by Application
9.3.1 Latin America Radioligand Therapy Market Size by Application (2017-2022)
9.3.2 Latin America Radioligand Therapy Market Size by Application (2023-2028)
9.3.3 Latin America Radioligand Therapy Market Share by Application (2017-2028)
9.4 Latin America Radioligand Therapy Market Size by Country
9.4.1 Latin America Radioligand Therapy Market Size by Country (2017-2022)
9.4.2 Latin America Radioligand Therapy Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Radioligand Therapy Market Size (2017-2028)
10.2 Middle East & Africa Radioligand Therapy Market Size by Used Radionuclides
10.2.1 Middle East & Africa Radioligand Therapy Market Size by Used Radionuclides (2017-2022)
10.2.2 Middle East & Africa Radioligand Therapy Market Size by Used Radionuclides (2023-2028)
10.2.3 Middle East & Africa Radioligand Therapy Market Share by Used Radionuclides (2017-2028)
10.3 Middle East & Africa Radioligand Therapy Market Size by Application
10.3.1 Middle East & Africa Radioligand Therapy Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Radioligand Therapy Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Radioligand Therapy Market Share by Application (2017-2028)
10.4 Middle East & Africa Radioligand Therapy Market Size by Country
10.4.1 Middle East & Africa Radioligand Therapy Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Radioligand Therapy Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Radioligand Therapy Introduction
11.1.4 Novartis Revenue in Radioligand Therapy Business (2017-2022)
11.1.5 Novartis Recent Developments
11.2 Advanced Accelerator Applications
11.2.1 Advanced Accelerator Applications Company Details
11.2.2 Advanced Accelerator Applications Business Overview
11.2.3 Advanced Accelerator Applications Radioligand Therapy Introduction
11.2.4 Advanced Accelerator Applications Revenue in Radioligand Therapy Business (2017-2022)
11.2.5 Advanced Accelerator Applications Recent Developments
11.3 Mercy Radiology
11.3.1 Mercy Radiology Company Details
11.3.2 Mercy Radiology Business Overview
11.3.3 Mercy Radiology Radioligand Therapy Introduction
11.3.4 Mercy Radiology Revenue in Radioligand Therapy Business (2017-2022)
11.3.5 Mercy Radiology Recent Developments
11.4 POINT Biopharma Global Inc
11.4.1 POINT Biopharma Global Inc Company Details
11.4.2 POINT Biopharma Global Inc Business Overview
11.4.3 POINT Biopharma Global Inc Radioligand Therapy Introduction
11.4.4 POINT Biopharma Global Inc Revenue in Radioligand Therapy Business (2017-2022)
11.4.5 POINT Biopharma Global Inc Recent Developments
11.5 Fusion Pharma
11.5.1 Fusion Pharma Company Details
11.5.2 Fusion Pharma Business Overview
11.5.3 Fusion Pharma Radioligand Therapy Introduction
11.5.4 Fusion Pharma Revenue in Radioligand Therapy Business (2017-2022)
11.5.5 Fusion Pharma Recent Developments
11.6 Telix Pharmaceuticals Ltd
11.6.1 Telix Pharmaceuticals Ltd Company Details
11.6.2 Telix Pharmaceuticals Ltd Business Overview
11.6.3 Telix Pharmaceuticals Ltd Radioligand Therapy Introduction
11.6.4 Telix Pharmaceuticals Ltd Revenue in Radioligand Therapy Business (2017-2022)
11.6.5 Telix Pharmaceuticals Ltd Recent Developments
11.7 Lantheus Holdings, Inc
11.7.1 Lantheus Holdings, Inc Company Details
11.7.2 Lantheus Holdings, Inc Business Overview
11.7.3 Lantheus Holdings, Inc Radioligand Therapy Introduction
11.7.4 Lantheus Holdings, Inc Revenue in Radioligand Therapy Business (2017-2022)
11.7.5 Lantheus Holdings, Inc Recent Developments
11.8 Bayer AG
11.8.1 Bayer AG Company Details
11.8.2 Bayer AG Business Overview
11.8.3 Bayer AG Radioligand Therapy Introduction
11.8.4 Bayer AG Revenue in Radioligand Therapy Business (2017-2022)
11.8.5 Bayer AG Recent Developments
11.9 Curium Pharma
11.9.1 Curium Pharma Company Details
11.9.2 Curium Pharma Business Overview
11.9.3 Curium Pharma Radioligand Therapy Introduction
11.9.4 Curium Pharma Revenue in Radioligand Therapy Business (2017-2022)
11.9.5 Curium Pharma Recent Developments
11.10 Precirix
11.10.1 Precirix Company Details
11.10.2 Precirix Business Overview
11.10.3 Precirix Radioligand Therapy Introduction
11.10.4 Precirix Revenue in Radioligand Therapy Business (2017-2022)
11.10.5 Precirix Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Radioligand Therapy Market Size Growth Rate by Used Radionuclides (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Actinium 225 (Ac-225)
Table 3. Key Players of Lutetium 177 (Lu-177)
Table 4. Key Players of Gallium 68 (Ga-68)
Table 5. Key Players of Fluorine 18 (F-18)
Table 6. Key Players of Other Radionuclides
Table 7. Global Radioligand Therapy Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 8. Global Radioligand Therapy Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Radioligand Therapy Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Radioligand Therapy Market Share by Region (2017-2022)
Table 11. Global Radioligand Therapy Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Radioligand Therapy Market Share by Region (2023-2028)
Table 13. Radioligand Therapy Market Trends
Table 14. Radioligand Therapy Market Drivers
Table 15. Radioligand Therapy Market Challenges
Table 16. Radioligand Therapy Market Restraints
Table 17. Global Radioligand Therapy Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Radioligand Therapy Revenue Share by Players (2017-2022)
Table 19. Global Top Radioligand Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioligand Therapy as of 2021)
Table 20. Ranking of Global Top Radioligand Therapy Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Radioligand Therapy Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Radioligand Therapy Product Solution and Service
Table 24. Date of Enter into Radioligand Therapy Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Radioligand Therapy Market Size by Used Radionuclides (2017-2022) & (US$ Million)
Table 27. Global Radioligand Therapy Revenue Market Share by Used Radionuclides (2017-2022)
Table 28. Global Radioligand Therapy Forecasted Market Size by Used Radionuclides (2023-2028) & (US$ Million)
Table 29. Global Radioligand Therapy Revenue Market Share by Used Radionuclides (2023-2028)
Table 30. Global Radioligand Therapy Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Radioligand Therapy Revenue Share by Application (2017-2022)
Table 32. Global Radioligand Therapy Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Radioligand Therapy Revenue Share by Application (2023-2028)
Table 34. North America Radioligand Therapy Market Size by Used Radionuclides (2017-2022) & (US$ Million)
Table 35. North America Radioligand Therapy Market Size by Used Radionuclides (2023-2028) & (US$ Million)
Table 36. North America Radioligand Therapy Market Size by Application (2017-2022) & (US$ Million)
Table 37. North America Radioligand Therapy Market Size by Application (2023-2028) & (US$ Million)
Table 38. North America Radioligand Therapy Market Size by Country (2017-2022) & (US$ Million)
Table 39. North America Radioligand Therapy Market Size by Country (2023-2028) & (US$ Million)
Table 40. Europe Radioligand Therapy Market Size by Used Radionuclides (2017-2022) & (US$ Million)
Table 41. Europe Radioligand Therapy Market Size by Used Radionuclides (2023-2028) & (US$ Million)
Table 42. Europe Radioligand Therapy Market Size by Application (2017-2022) & (US$ Million)
Table 43. Europe Radioligand Therapy Market Size by Application (2023-2028) & (US$ Million)
Table 44. Europe Radioligand Therapy Market Size by Country (2017-2022) & (US$ Million)
Table 45. Europe Radioligand Therapy Market Size by Country (2023-2028) & (US$ Million)
Table 46. Asia Pacific Radioligand Therapy Market Size by Used Radionuclides (2017-2022) & (US$ Million)
Table 47. Asia Pacific Radioligand Therapy Market Size by Used Radionuclides (2023-2028) & (US$ Million)
Table 48. Asia Pacific Radioligand Therapy Market Size by Application (2017-2022) & (US$ Million)
Table 49. Asia Pacific Radioligand Therapy Market Size by Application (2023-2028) & (US$ Million)
Table 50. Asia Pacific Radioligand Therapy Market Size by Region (2017-2022) & (US$ Million)
Table 51. Asia Pacific Radioligand Therapy Market Size by Region (2023-2028) & (US$ Million)
Table 52. Latin America Radioligand Therapy Market Size by Used Radionuclides (2017-2022) & (US$ Million)
Table 53. Latin America Radioligand Therapy Market Size by Used Radionuclides (2023-2028) & (US$ Million)
Table 54. Latin America Radioligand Therapy Market Size by Application (2017-2022) & (US$ Million)
Table 55. Latin America Radioligand Therapy Market Size by Application (2023-2028) & (US$ Million)
Table 56. Latin America Radioligand Therapy Market Size by Country (2017-2022) & (US$ Million)
Table 57. Latin America Radioligand Therapy Market Size by Country (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Radioligand Therapy Market Size by Used Radionuclides (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Radioligand Therapy Market Size by Used Radionuclides (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Radioligand Therapy Market Size by Application (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Radioligand Therapy Market Size by Application (2023-2028) & (US$ Million)
Table 62. Middle East and Africa Radioligand Therapy Market Size by Country (2017-2022) & (US$ Million)
Table 63. Middle East and Africa Radioligand Therapy Market Size by Country (2023-2028) & (US$ Million)
Table 64. Novartis Company Details
Table 65. Novartis Business Overview
Table 66. Novartis Radioligand Therapy Product
Table 67. Novartis Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 68. Novartis Recent Developments
Table 69. Advanced Accelerator Applications Company Details
Table 70. Advanced Accelerator Applications Business Overview
Table 71. Advanced Accelerator Applications Radioligand Therapy Product
Table 72. Advanced Accelerator Applications Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 73. Advanced Accelerator Applications Recent Developments
Table 74. Mercy Radiology Company Details
Table 75. Mercy Radiology Business Overview
Table 76. Mercy Radiology Radioligand Therapy Product
Table 77. Mercy Radiology Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 78. Mercy Radiology Recent Developments
Table 79. POINT Biopharma Global Inc Company Details
Table 80. POINT Biopharma Global Inc Business Overview
Table 81. POINT Biopharma Global Inc Radioligand Therapy Product
Table 82. POINT Biopharma Global Inc Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 83. POINT Biopharma Global Inc Recent Developments
Table 84. Fusion Pharma Company Details
Table 85. Fusion Pharma Business Overview
Table 86. Fusion Pharma Radioligand Therapy Product
Table 87. Fusion Pharma Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 88. Fusion Pharma Recent Developments
Table 89. Telix Pharmaceuticals Ltd Company Details
Table 90. Telix Pharmaceuticals Ltd Business Overview
Table 91. Telix Pharmaceuticals Ltd Radioligand Therapy Product
Table 92. Telix Pharmaceuticals Ltd Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 93. Telix Pharmaceuticals Ltd Recent Developments
Table 94. Lantheus Holdings, Inc Company Details
Table 95. Lantheus Holdings, Inc Business Overview
Table 96. Lantheus Holdings, Inc Radioligand Therapy Product
Table 97. Lantheus Holdings, Inc Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 98. Lantheus Holdings, Inc Recent Developments
Table 99. Bayer AG Company Details
Table 100. Bayer AG Business Overview
Table 101. Bayer AG Radioligand Therapy Product
Table 102. Bayer AG Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 103. Bayer AG Recent Developments
Table 104. Curium Pharma Company Details
Table 105. Curium Pharma Business Overview
Table 106. Curium Pharma Radioligand Therapy Product
Table 107. Curium Pharma Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 108. Curium Pharma Recent Developments
Table 109. Precirix Company Details
Table 110. Precirix Business Overview
Table 111. Precirix Radioligand Therapy Product
Table 112. Precirix Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 113. Precirix Recent Developments
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Radioligand Therapy Market Share by Used Radionuclides: 2021 VS 2028
Figure 2. Actinium 225 (Ac-225) Features
Figure 3. Lutetium 177 (Lu-177) Features
Figure 4. Gallium 68 (Ga-68) Features
Figure 5. Fluorine 18 (F-18) Features
Figure 6. Other Radionuclides Features
Figure 7. Global Radioligand Therapy Market Share by Application: 2021 VS 2028
Figure 8. Neuroendocrine Neoplasms Case Studies
Figure 9. Prostate Cancer Case Studies
Figure 10. Radioligand Therapy Report Years Considered
Figure 11. Global Radioligand Therapy Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 12. Global Radioligand Therapy Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Radioligand Therapy Market Share by Region: 2021 VS 2028
Figure 14. Global Radioligand Therapy Market Share by Players in 2021
Figure 15. Global Top Radioligand Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioligand Therapy as of 2021)
Figure 16. The Top 10 and 5 Players Market Share by Radioligand Therapy Revenue in 2021
Figure 17. North America Radioligand Therapy Market Size YoY (2017-2028) & (US$ Million)
Figure 18. North America Radioligand Therapy Market Size Market Share by Used Radionuclides (2017-2028)
Figure 19. North America Radioligand Therapy Market Size Market Share by Application (2017-2028)
Figure 20. North America Radioligand Therapy Market Size Share by Country (2017-2028)
Figure 21. United States Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Canada Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Europe Radioligand Therapy Market Size YoY (2017-2028) & (US$ Million)
Figure 24. Europe Radioligand Therapy Market Size Market Share by Used Radionuclides (2017-2028)
Figure 25. Europe Radioligand Therapy Market Size Market Share by Application (2017-2028)
Figure 26. Europe Radioligand Therapy Market Size Share by Country (2017-2028)
Figure 27. Germany Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. France Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. U.K. Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Italy Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Russia Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Nordic Countries Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Asia-Pacific Radioligand Therapy Market Size YoY (2017-2028) & (US$ Million)
Figure 34. Asia Pacific Radioligand Therapy Market Size Market Share by Used Radionuclides (2017-2028)
Figure 35. Asia Pacific Radioligand Therapy Market Size Market Share by Application (2017-2028)
Figure 36. Asia Pacific Radioligand Therapy Market Size Share by Region (2017-2028)
Figure 37. China Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Japan Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. South Korea Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Southeast Asia Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. India Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Australia Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 43. Latin America Radioligand Therapy Market Size YoY (2017-2028) & (US$ Million)
Figure 44. Latin America Radioligand Therapy Market Size Market Share by Used Radionuclides (2017-2028)
Figure 45. Latin America Radioligand Therapy Market Size Market Share by Application (2017-2028)
Figure 46. Latin America Radioligand Therapy Market Size Share by Country (2017-2028)
Figure 47. Mexico Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Brazil Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Middle East & Africa Radioligand Therapy Market Size YoY (2017-2028) & (US$ Million)
Figure 50. Middle East and Africa Radioligand Therapy Market Size Market Share by Used Radionuclides (2017-2028)
Figure 51. Middle East and Africa Radioligand Therapy Market Size Market Share by Application (2017-2028)
Figure 52. Middle East and Africa Radioligand Therapy Market Size Share by Country (2017-2028)
Figure 53. Turkey Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Saudi Arabia Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. UAE Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. Novartis Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 57. Advanced Accelerator Applications Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 58. Mercy Radiology Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 59. POINT Biopharma Global Inc Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 60. Fusion Pharma Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 61. Telix Pharmaceuticals Ltd Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 62. Lantheus Holdings, Inc Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 63. Bayer AG Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 64. Curium Pharma Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 65. Precirix Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

---